Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Alcon N 2.Linie is a Swiss pharmaceutical and medical devices company specializing in eye care solutions. The company develops, manufactures, and markets a comprehensive portfolio of products designed to address various ophthalmological conditions and needs. Its offerings include prescription medications for eye diseases, surgical devices for ophthalmic procedures, and over-the-counter eye care products for consumers. Alcon serves multiple market segments including hospitals, surgical centers, ophthalmology clinics, optometry practices, and retail channels. The company operates globally, providing solutions for conditions such as dry eye disease, glaucoma, cataracts, and retinal disorders. As a prominent player in the eye care industry, Alcon plays a significant role in advancing treatment options and improving vision outcomes for patients worldwide. The company combines innovation in pharmaceutical development with advances in surgical technology to address diverse eye health needs across different patient populations and healthcare settings.
13.08% operating margin is respectable but not wide. ROIC at 5.12%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$10.63B
Net Income (TTM)
$819M
Op. Margin
11.13%
ROIC
5.12%
Cash Flow & Balance Sheet
FCF (TTM)
$1.59B
Op. Cash Flow (TTM)
$2.36B
Net Debt
N/A
Cash & Equiv.
N/A
Continue Research